Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
-
- Uma Prabhakar
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- Hiroshi Maeda
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- Rakesh K. Jain
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- Eva M. Sevick-Muraca
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- William Zamboni
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- Omid C. Farokhzad
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- Simon T. Barry
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- Alberto Gabizon
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- Piotr Grodzinski
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
-
- David C. Blakey
- Authors' Affiliations: 1Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, Maryland; 2Institute for DDS Research, Sojo University, Kumamoto, Japan; 3Harvard Medical School and Massachusetts General Hospital; 4Harvard Medical School and Brigham and Womens Hospital, Boston, Massachusetts; 5Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, Texas; 6UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; 7AstraZeneca, Alderley Park, Macclesfield, United Kingdom; and 8Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel
抄録
<jats:title>Abstract</jats:title> <jats:p>Enhanced permeability of the tumor vasculature allows macromolecules to enter the tumor interstitial space, whereas the suppressed lymphatic filtration allows them to stay there. This phenomenon, enhanced permeability and retention (EPR), has been the basis of nanotechnology platforms to deliver drugs to tumors. However, progress in developing effective drugs using this approach has been hampered by heterogeneity of EPR effect in different tumors and limited experimental data from patients on effectiveness of this mechanism as related to enhanced drug accumulation. This report summarizes the workshop discussions on key issues of the EPR effect and major gaps that need to be addressed to effectively advance nanoparticle-based drug delivery. Cancer Res; 73(8); 2412–7. ©2013 AACR.</jats:p>
収録刊行物
-
- Cancer Research
-
Cancer Research 73 (8), 2412-2417, 2013-04-15
American Association for Cancer Research (AACR)